Cd44 Knockout cell line (Panc02)
Catalog Number: KO01214
Price: Online Inquiry
Catalog Number: KO01214
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Cd44 Knockout cell line (Panc02) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epithelioid, adherent cell |
Passage ratio | 1:3~1:4 |
species | Mouse |
Gene | Cd44 |
Gene ID | 12505 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 95%DMEM+5% FBS |
Parental Cell Line | Panc02 |
Quality Control | Genotype: Cd44 Knockout cell line (Panc02) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | CD44 antigenprovided by MGI |
Also known as | Ly-24; Pgp-1; HERMES |
Gene Description | Enables cargo receptor activity; hyaluronic acid binding activity; and type II transforming growth factor beta receptor binding activity. Contributes to cytokine binding activity and cytokine receptor activity. Involved in several processes, including hyaluronan catabolic process; negative regulation of T cell activation; and regulation of intracellular signal transduction. Acts upstream of or within several processes, including Wnt signaling pathway; morphogenesis of a branching epithelium; and wound healing involved in inflammatory response. Located in basolateral plasma membrane; external side of plasma membrane; and microvillus. Part of macrophage migration inhibitory factor receptor complex. Is expressed in several structures, including alimentary system; branchial arch; central nervous system; genitourinary system; and limb. Human ortholog(s) of this gene implicated in breast carcinoma (multiple); carcinoma (multiple); and prostate cancer. Orthologous to human CD44 (CD44 molecule (IN blood group)). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Broad expression in lung adult (RPKM 13.1), spleen adult (RPKM 8.5) and 23 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.